Improvement of Cognitive Function after Continuous Positive Airway Pressure Treatment for Subacute Stroke Patients with Obstructive Sleep Apnea: A Randomized Controlled Trial

Abstract

Background: Obstructive sleep apnea (OSA) is common after stroke. Various studies on continuous positive airway pressure (CPAP) therapy for OSA after stroke have been published. However, there have been no studies from Korea and Asia. The present Korean study aimed to determine whether CPAP treatment during inpatient rehabilitation of stroke patients with sleep disorders, especially OSA, improves function, cognition, sleep quality, and daytime sleepiness. Methods: This single-blind randomized controlled study included 40 stroke patients with OSA between November 2017 and November 2018. The patients were divided into the CPAP treatment group (CPAP and rehabilitation; n = 20) and control group (only rehabilitation; n = 20). The intervention period was 3 weeks. The primary outcomes were function and cognition improvements, and the secondary outcomes were sleep-related improvements. Results: CPAP treatment started at an average of 4.6 ± 2.8 days after admission. Both groups showed improvements in stroke severity, function, and cognition after the 3-week intervention. However, after the intervention, the degree of change in attention and calculation was significantly higher in the CPAP treatment group than in the control group. Additionally, the improvements in sleep quality and daytime sleepiness were greater in the CPAP treatment group than in the control group. Conclusion: CPAP treatment can improve cognitive function, sleep quality, and daytime sleepiness, and it should be considered as part of the rehabilitation program for patients with stroke. Our findings might help in the treatment of stroke patients with OSA in Korea.

Full text

brain
sciences
Article
Improvement of Cognitive Function after Continuous
Positive Airway Pressure Treatment for Subacute
Stroke Patients with Obstructive Sleep Apnea:
A Randomized Controlled Trial
Howook Kim 1, Soobin Im 1, Jun il Park 1, Yeongwook Kim 1, Min Kyun Sohn 1,2,3 and
Sungju Jee 1,2,3,*
1Department of Rehabilitation Medicine, Chungnam National University Hospital, Daejeon 35015, Korea;
bulam5630@cnu.ac.kr (H.K.); ysbcool@cnuh.co.kr (S.I.); uniwater@naver.com (J.i.P.);
kyu0922@cnuh.co.kr (Y.K.); mksohn@cnuh.co.kr (M.K.S.)
2Daejeon Chungcheong Regional Cardiocerebrovascular Center, Chungnam National University Hospital,
Daejeon 35015, Korea
3Daejeon Chungcheong Regional Medical Rehabilitation Center, Chungnam National University Hospital,
Daejeon 35015, Korea
*Correspondence: drjeesungju@hanmail.net; Tel.: +82-42-338-2423; Fax: +82-42-338-2461
Received: 5 September 2019; Accepted: 23 September 2019; Published: 25 September 2019


Abstract: Background:
Obstructive sleep apnea (OSA) is common after stroke. Various studies
on continuous positive airway pressure (CPAP) therapy for OSA after stroke have been published.
However, there have been no studies from Korea and Asia. The present Korean study aimed to
determine whether CPAP treatment during inpatient rehabilitation of stroke patients with sleep
disorders, especially OSA, improves function, cognition, sleep quality, and daytime sleepiness.
Methods:
This single-blind randomized controlled study included 40 stroke patients with OSA
between November 2017 and November 2018. The patients were divided into the CPAP treatment
group (CPAP and rehabilitation; n=20) and control group (only rehabilitation; n=20). The intervention
period was 3 weeks. The primary outcomes were function and cognition improvements, and the
secondary outcomes were sleep-related improvements.
Results:
CPAP treatment started at an average
of 4.6
±
2.8 days after admission. Both groups showed improvements in stroke severity, function,
and cognition after the 3-week intervention. However, after the intervention, the degree of change in
attention and calculation was significantly higher in the CPAP treatment group than in the control
group. Additionally, the improvements in sleep quality and daytime sleepiness were greater in
the CPAP treatment group than in the control group.
Conclusion:
CPAP treatment can improve
cognitive function, sleep quality, and daytime sleepiness, and it should be considered as part of the
rehabilitation program for patients with stroke. Our findings might help in the treatment of stroke
patients with OSA in Korea.
Keywords: subacute stroke; CPAP; obstructive sleep apnea; cognition
1. Introduction
Approximately 795,000 people experience new strokes or recurrent strokes annually; 610,000 of
these are first attacks, and 185,000 are recurrent attacks [
1
]. Stroke is a major cause of disability, and it
impairs ambulation activities, activities of daily living (ADL), community integration, and quality of
life (QOL), resulting in serious personal, social, and economic losses [
1
–
4
]. Because stroke recurrence is
common, risk factors related to recurrence should be identified and controlled. Stroke has various risk
Brain Sci. 2019,9, 252; doi:10.3390/brainsci9100252 www.mdpi.com/journal/brainsci

Brain Sci. 2019,9, 252 2 of 13
factors [
1
], one of which is sleep disordered breathing (SDB) [
1
,
5
–
12
]. SDB is commonly observed after
stroke, and it affects patients’ quality of sleep and QOL [
13
–
16
]. In addition, SDB affects cognition and
functional recovery in patients with stroke [
17
–
19
]. According to Hermann et al., 60–70% of patients
with stroke have SDB, which is much higher than that of the normal population [
20
]. Other studies
have reported SDB in 50–70% of patients with acute and subacute stroke [21–23].
SDB in patients with stroke can lead to neurological deterioration and prolonged
hospitalization [17,19,24,25]
, and it can affect post-stroke mortality [
16
,
26
–
28
] or short- and long-term
prognoses in patients with stroke [
14
,
18
,
29
,
30
]. Obstructive sleep apnea (OSA) is the most common form
of SDB, and it is caused by airflow disturbance due to airway obstruction [
31
–
33
]. OSA may improve
in the subacute stages after stroke, but 50% of patients with stroke may still have an apnea–hypopnea
index (AHI) >10 during the 2–3 months after onset [
34
]. Continuous positive airway pressure (CPAP)
therapy is the main treatment for OSA [
35
,
36
]. In a study of SDB in patients with acute stroke, CPAP
treatment improved patients’ exercise and function at 3 weeks after stroke onset, and compliance with
treatment was high [
29
]. In addition, the AHI was significantly lower in the CPAP group than in the
control group at 3 days after the stroke onset [37].
Parra et al. reported that the CPAP-treated group showed a significant improvement in the
modified Rankin scale (mRS) score, Canadian Cardiovascular Society scale score, and cardiovascular
disease and mortality rates compared to the control group [
38
]. According to a meta-analysis of
randomized controlled trials (RCTs) published in 2018, 10 RCTs showed neurofunctional improvement
with CPAP treatment [
39
], and improvement of long-term survival was confirmed in a study by
Parra et al. [40]
. Therefore, it is thought that the treatment of OSA after stroke has a good effect on the
recovery of function after stroke. Studies on CPAP therapy for OSA after stroke have been continuously
published [
6
,
26
,
29
,
31
,
38
–
41
]. In Korea and Asia, however, such studies have not been performed; thus,
it is necessary to study this topic in order to improve the recovery of patients with stroke. Therefore,
the purposes of this study were to determine whether CPAP treatment during inpatient rehabilitation
of stroke patients with sleep disorders, especially OSA, significantly improves function or cognition,
and to compare the improvement of sleep quality and daytime sleepiness scale score between patients
with and without CPAP treatment.
2. Methods
2.1. Ethical Statement
Written consent was obtained from all patients or caregivers before study participation, and the
study protocol was approved by the Institutional Review Board of Chungnam National University
Hospital approved this study (No. 2017-08-051-002). The study was also registered in the International
Clinical Trials Registry Platform database (CRiS, Clinical Research Information Service; Clinical Trial
Registration No. KCT0003688).
2.2. Study Design
This study was performed in Chungnam University Hospital hospital, Republic of Korea
using a single-blind RCT design. Staffat our hospital treated patients with hyperacute stroke in
the cardiocerebrovascular center, and our hospital has a transfer system in the inpatient medical
rehabilitation center during the acute and subacute periods after stroke. A blinded outcome analyzer
collected cognitive and functional outcomes and sleep-related parameters. Previous studies have
defined an AHI >30/h as severe OSA, but in this study, we evaluated patients with an AHI
≥
20/h [
42
,
43
].
Patients with OSA were randomly assigned to either a CPAP treatment group or a control group
(rehabilitation only). Clinical data were evaluated at the time of admission to the Department of
Rehabilitation Medicine and after the 3-week intervention period.

Brain Sci. 2019,9, 252 3 of 13
2.3. Patients
This prospective study collected demographic and clinical data, including residual disability,
activity limitations, and QOL, of patients with subacute stroke diagnosed by magnetic resonance
imaging (MRI) or computed tomography (CT). Among the patients who were screened from November
2017 to November 2018 (n=98), 43 patients were enrolled in this study. The data of the patients who
participated in the final evaluation after the intervention (n=40) were analyzed. The inclusion criteria
were as follows: (1) A diagnosis of cerebral infarction or hemorrhage in the brain by CT or MRI; (2) only
patients with predominant OSA (>50% of the respiratory events were obstructive type) exhibiting at
least AHI
≥
20/h were included, except those with central apnea or mixed apnea; (3) patients between
18 and 80 years of age; (4) patients admitted within 7 days to 6 months after stroke onset; (5) patients
with cognitive functions capable of simple command obey; and (6) patients who provided informed
consent. We excluded patients with any of the following: (1) A history of traumatic brain damage or
brain tumor; (2) a diagnosis of mild-to-moderate obstructive sleep apnea (OSA); (3) baseline oxygen
saturation <95%; (4) the presence of acute or chronic cardiopulmonary diseases that affects pulmonary
function; (5) presence of neuromuscular diseases (e.g., amyotrophic lateral sclerosis and myasthenia
gravis); and (6) an unstable medical condition preventing completion of the clinical trial.
2.4. Sleep Examination
We performed bedside sleep examination using a portable polysomnography called Stardust II
(Philips Respironics Inc., Murrysville, PA, USA). This multichannel device recorded the following
diagnostic parameters: Oxygen saturation, pulse rate, nasal airflow, and respiratory effort by chest
wall motion. We performed the sleep examination from 9 PM to 6 AM, without overnight supervision.
A trained sleep technologist analyzed the sleep data using the American Academy of Sleep Medicine
criteria [
44
]. Hypopnea was defined as a reduction of airflow by
≥
50% for at least 10 s, followed by
oxygen desaturation
≥
3%, and apnea was defined as a reduction of airflow by
≥
90% for at least 10 s.
Apneas with thoracic motion without chest wall motion or with an initial lack of motion followed by
respiratory effort were classified as obstructive, central, or mixed, respectively. The AHI was defined
as the mean number of apneas and hypopneas per hour. The obstructive apnea index and central
apnea index were defined as the mean numbers of obstructive apneas and central apnea events per
hour, respectively. The oxygen desaturation index (ODI) was defined as the mean number of oxygen
desaturations
≥
3% per hour. Sleep apnea was classified as obstructive or central, according to the type
of predominant event. Predominant OSA was diagnosed when >50% of the respiratory events were of
the obstructive type [
38
]. Sleep quality was assessed before and after the intervention by using the
Epworth Sleepiness Scale (ESS) [
45
–
47
]. We obtained answers for the ESS from cooperative patients, or
alternatively, from patients’ relatives. The ESS assesses daytime sleepiness, and it clinically defines
a score >10 as excessive daytime sleepiness.
2.5. Randomization
After explaining the trial to the patients and receiving written informed consent, the physicians
included in the study reported to the researcher that the patient was recruited into the study.
The researcher allocated the patients to the CPAP treatment or control group using a random
number table.
2.6. Intervention
Aside from nighttime CPAP therapy, all patients underwent conventional rehabilitation of the
same degree on the schedule that was provided to them. Neither group performed treatments such
as use of CNS stimulants such as methylphenidate, cognitive rehabilitation, or non-invasive brain
stimulation. CPAP treatment was set up and monitored by one rehabilitation physician and two nurses
who worked in the stroke rehabilitation ward. Personalized instructions were given to patients and

Brain Sci. 2019,9, 252 4 of 13
caregivers before CPAP treatment, and written manuals were provided for the CPAP devices. Patients
assigned to the CPAP treatment group were given a proper nasal or oronasal mask and continuous
air pressure at night. Patients receiving CPAP treatment were treated with REMstar CPAP 60 Series
A-Flex (Philips Respironics Inc., Murrysville, PA, USA) at a pressure setting with a 12 cmH2O. Patients
were defined as having received adequate treatment if they had maintained CPAP for an average of
>4 h over 3 weeks.
2.7. Demographic Data
2.7.1. Primary Outcomes
Neurological and functional outcomes and sleep examination data were assessed before and after
the intervention. The severity of stroke was assessed by the Korean version of the National Institute
of Health Stroke Scale (NIHSS) and the functional outcome of patients by functional ambulation
categories (FAC), modified Rankin Scale (MRS), and Berg Balance Scale (BBS). The activity of daily
living was assessed by the Korean version of the modified Barthel index (K-MBI), and the quality of life
was assessed by EuroQol-5 Dimension (EQ-5D). The patient’s cognitive status was evaluated by the
Korean version of the Mini-Mental State Examination (K-MMSE). The improvement of neurological
function and sleep quality was determined based on the difference between the results before and
after the intervention. The primary outcome data analysis was performed by assessing the change of
neurological severity and improvement of cognitive and functional assessments. We also assessed the
level of improvement in each K-MMSE domain in the cognitive outcome. By using the K-MMSE data
of each patient, we obtained data on “orientation to time, orientation to place, registration, attention
and calculation, recall, language and drawing” [
48
], and evaluated the improvement level of data for
each K-MMSE domain.
2.7.2. Secondary Outcome
Secondary outcome data analysis was performed by evaluating improvement of the sleep
examination data, such as obstructive apnea and AHI, and the improvement of the daytime sleepiness
based on the ESS.
2.8. Statistical Analysis
Statistical analysis of data for patients who completed the intervention was performed, and the
two-way analysis of variance was used to compare the differences in clinical data between the CPAP
treatment and control groups. To evaluate the relationship between the additional CPAP treatment
and each outcome, regression analyses were performed. Statistical analyses were performed using
IBM SPSS Statistics version 23.0 (IBM Corp., Armonk, NY, USA). A p-value <0.05 was considered
statistically significant.
3. Results
We screened 98 patients with subacute stroke admitted to rehabilitation units between November
2017 and November 2018. Forty-three patients were predominant OSA patients with at least
AHI ≥20
.
These patients were randomly assigned to the CPAP treatment group (n=23) or control group (n=20).
However, 3 (13.0%) of 23 patients who started CPAP treatment refused CPAP because of mechanical
discomfort. Therefore, the CPAP treatment group ultimately consisted of 20 patients, and control
group included 20 patients (Figure 1). CPAP treatment started at an average of 4.6
±
2.8 days after
a patient with stroke was admitted to the Department of Rehabilitation Medicine. Patients were mainly
men, and they had ischemic stroke and hypertension (Table 1). In the CPAP group, 2 patients with
thrombolysis and 4 patients with thrombectomy were enrolled in the CPAP group. Three patients
underwent hemorrhage removal and 3 patients underwent neurologic observation. In the control
group, 2 patients with thrombolysis, 3 patients with thrombectomy, 2 patients with hemorrhage

Brain Sci. 2019,9, 252 5 of 13
removal, and 2 patients with neurologic observation were enrolled in the control group. Most initial
assessment data in both groups were similar. However, there was a difference between the CPAP
treatment and control groups in the evaluation items related to quality of sleep, such as central apnea
(5.5
±
13.2 and 4.4
±
14.0, respectively), obstructive apnea (26.5
±
17.5 and 15.2
±
13.4, respectively),
mixed apnea (3.3
±
6.9 and 5.2
±
10.3, respectively), and AHI (44.4
±
16.8 and 34.9
±
17.2, respectively).
The severity of stroke was similar in both groups (NIHSS score 6–7), and there was no significant
difference in the measurement of functional or cognitive status. The subject’s body mass index (BMI)
was less than 25 in both groups, which was less than other stroke subjects in the world.
Brain Sci. 2019, 9, x FOR PEER REVIEW 5 of 12
the CPAP treatment and control groups in the evaluation items related to quality of sleep, such as
central apnea (5.5 ± 13.2 and 4.4 ± 14.0, respectively), obstructive apnea (26.5 ± 17.5 and 15.2 ± 13.4,
respectively), mixed apnea (3.3 ± 6.9 and 5.2 ± 10.3, respectively), and AHI (44.4 ± 16.8 and 34.9 ± 17.2,
respectively). The severity of stroke was similar in both groups (NIHSS score 6–7), and there was no
significant difference in the measurement of functional or cognitive status. The subject's body mass
index (BMI) was less than 25 in both groups, which was less than other stroke subjects in the world.
Figure 1. Flow chart to study population. PSG, polysomnography; OSA, obstructive sleep apnea;
CPAP, continuous positive airway pressure.
Table 1. Clinical characteristics of intervention group.
CPAP (n = 20) Control (n = 20) p-Value
Sex, n (men/women) 13/7 (65.0/35.0%) 16/4 (80.0/20.0%) 0.429
Age (years) 63.3 ± 13.1 66.9 ± 12.3 0.369
Type of stroke, n (ischemic/hemorrhagic) 14/6 (70.0/30.0%) 16/4 (80.0/20.0%) 0.602
Lesion type, n (Supratentorial/Infratentorial) 14/6 (70.0/30.0%) 11/9 (55.0/45.0%) 0.429
Ischemic group primary treatment, n
(Thrombolysis/Thrombectomy) 2/4 (10.0/20.0%) 2/3 (10.0/15.0%) 0.000
Hemorrhagic group primary treatment, n
(observation/hemorrhage removal) 3/3 (50.0/50.0%) 2/2 (50.0/50.0%) 0.000
BMI 23.3 ± 3.7 24.4 ± 3.9 0.370
LOS 38.6 ± 11.4 37.8 ± 14.8 0.849
NIHSS 6.7 ± 3.5 6.5 ± 5.7 0.869
K-MMSE 18.6 ± 7.7 17.5 ± 9.1 0.668
FAC 1.3 ± 1.5 1.7 ± 2.0 0.474
MRS 3.9 ± 1.0 3.5 ± 1.2 0.207
BBS 15.5 ± 17.1 22.9 ± 22.9 0.251
K-MBI 43.1 ± 26.5 45.8 ± 31.6 0.775
HTN (+/−) 13/7 (65.0/35.0%) 15/5 (75.0/25.0%) 0.602
Figure 1.
Flow chart to study population. PSG, polysomnography; OSA, obstructive sleep apnea;
CPAP, continuous positive airway pressure.
Table 1. Clinical characteristics of intervention group.
CPAP (n=20) Control (n=20) p-Value
Sex, n(men/women) 13/7 (65.0/35.0%) 16/4 (80.0/20.0%) 0.429
Age (years) 63.3 ±13.1 66.9 ±12.3 0.369
Type of stroke, n
(ischemic/hemorrhagic) 14/6 (70.0/30.0%) 16/4 (80.0/20.0%) 0.602
Lesion type, n
(Supratentorial/Infratentorial) 14/6 (70.0/30.0%) 11/9 (55.0/45.0%) 0.429
Ischemic group primary treatment, n
(Thrombolysis/Thrombectomy) 2/4 (10.0/20.0%) 2/3 (10.0/15.0%) 0.000
Hemorrhagic group primary
treatment, n
(observation/hemorrhage removal)
3/3 (50.0/50.0%) 2/2 (50.0/50.0%) 0.000
BMI 23.3 ±3.7 24.4 ±3.9 0.370
LOS 38.6 ±11.4 37.8 ±14.8 0.849
NIHSS 6.7 ±3.5 6.5 ±5.7 0.869

Brain Sci. 2019,9, 252 6 of 13
Table 1. Cont.
CPAP (n=20) Control (n=20) p-Value
K-MMSE 18.6 ±7.7 17.5 ±9.1 0.668
FAC 1.3 ±1.5 1.7 ±2.0 0.474
MRS 3.9 ±1.0 3.5 ±1.2 0.207
BBS 15.5 ±17.1 22.9 ±22.9 0.251
K-MBI 43.1 ±26.5 45.8 ±31.6 0.775
HTN (+/−) 13/7 (65.0/35.0%) 15/5 (75.0/25.0%) 0.602
DM (+/−) 4/16 (20.0/80.0%) 7/13 (35.0/65.0%) 0.429
EQ-5D 0.3 ±0.3 0.3 ±1.3 0.612
ESS 6.0 ±5.4 6.7 ±5.2 0.677
Central apnea 5.5 ±13.2 4.4 ±14.0 0.796
Obstructive apnea 26.5 ±17.5 15.2 ±13.4 0.028 *
Mixed apnea 3.3 ±6.9 5.2 ±10.3 0.503
Hypopnea 9.1 ±8.9 10.1 ±7.4 0.699
AHI 44.4 ±16.8 34.9 ±17.2 0.085
Snore flag index 62.6 ±76.3 42.0 ±63.9 0.359
Desaturation index 43.3 ±18.4 34.4 ±20.2 0.156
OSA, obstructive sleep apnea; BMI, body mass index; LOS, length of stay; NIHSS, Korean version of the National
Institute of Health Stroke Scale; MMSE, Korean version of the Mini-Mental State Examination; FAC, functional
ambulation categories; MRS, modified Rankin Scale; BBS, Berg Balance Scale; K-MBI, Korean version of the modified
Barthel index; HTN, hypertension; DM, diabetes mellitus; EQ-5D, EuroQol-5 Dimension; ESS, Epworth Sleepiness
Scale; AHI, apnea–hypopnea index; * p-value <0.05.
3.1. Primary Outcome Analysis (Functional and Cognitive Outcomes)
Both groups showed improvements in stroke severity, function, and cognition after the intervention
compared with before the intervention (Table 2). The degree of improvement was similar in both
groups, but the CPAP treatment group showed a better trend in stroke severity, balance and gait
levels, and cognition than the control group. Although the degree of improvement of neurological and
functional measures was better after the intervention in the CPAP treatment group than in the control
group, no statistical significant difference was observed. However, the CPAP treatment group showed
a significantly higher degree of change in the cognitive domain than the control group after the 3-week
intervention period (K-MMSE score 4.0
±
3.4 vs. 2.2
±
1.9; p=0.045). We assessed the cognitive-related
domains of the patients to determine which one showed more improvement. Specifically, the CPAP
treatment group showed significant improvement in the attention and calculation domain (p=0.001),
but no significant improvement in the other cognitive domains (Table 3).
Table 2. Comparison of clinical outcome between CPAP and control group.
CPAP (n=20) Control (n=20) p-Value
∆NIHSS −1.5 ±1.3 −1.1 ±1.5 0.157
∆MMSE 4.0 ±3.4 2.2 ±1.9 0.045 *
∆FAC 0.8 ±1.0 0.9 ±1.0 0.862
∆MRS −0.8 ±0.8 −0.4 ±0.6 0.142
∆BBS 10.0 ±10.3 8.7 ±10.7 0.583
∆K-MBI 14.0 ±9.8 13.5 ±9.9 0.873
∆EQ-5D 0.2 ±0.2 0.2 ±0.3 0.282
∆
, difference in score between pre-intervention–post-intervention. CPAP, continuous positive airway pressure;
NIHSS, Korean version of the National Institute of Health Stroke Scale; MMSE, Korean version of the Mini-Mental
State Examination; FAC, functional ambulation categories; MRS, modified Rankin Scale; BBS, Berg Balance Scale;
K-MBI, Korean version of the modified Barthel index; EQ-5D, EuroQol-5 Dimension. * p-value <0.05.

Brain Sci. 2019,9, 252 7 of 13
Table 3. Comparison of cognitive outcome between CPAP and control group.
CPAP (n=20) Control (n=20) p-Value
∆Orientation to time (5) 0.7 ±1.0 0.1 ±1.4 0.055
∆Orientation to place (5) 1.0 ±1.1 0.6 ±0.9 0.155
∆Registration (3) 0.1 ±0.4 0.2 ±0.7 0.554
∆Attention and calculation (5) 1.4 ±0.8 0.3 ±1.3 0.001 *
∆Recall (3) 0.3 ±1.1 0.4 ±0.6 0.558
∆Language (8) 0.5 ±0.9 0.8 ±1.1 0.501
∆Drawing (1) 0.1 ±0.4 0.1 ±0.6 0.710
∆Total (30) 4.0 ±3.4 2.2 ±1.9 0.045 *
∆
, difference in score between pre-intervention–post-intervention. CPAP, continuous positive airway pressure.
*p-value <0.05.
3.2. Secondary Outcome Analysis (Sleep Examination Data)
CPAP treatment was performed for 3 weeks and follow-up evaluation was performed at 3 time
points after treatment (Figure 2). All patients in the CPAP treatment group received CPAP treatment
during the nighttime after the CPAP adaptation period, and they were highly compliant (>4 h/day,
≥
5 days a week). However, in this study, compliance with CPAP treatment was not accurately measured.
During the hospital stay, the nurse in the ward checked the patients’ application of the CPAP machine
and educated the caregiver on how to measure the wearing time. As a result of the sleep examination,
the CPAP treatment group showed better improvement in the ESS score, central apnea, obstructive
apnea, AHI, snore flag index, and ODI than the control group. Especially, the CPAP treatment group
(n=20) showed a significant decrease in the AHI (17.9
±
12.8 vs.
−
3.0
±
9.7, p=0.001) and obstructive
apnea (
−
13.0
±
14.1 vs. 1.6
±
10.6, p=0.001) compared with the control group. In addition, significant
improvement was observed in the CPAP treatment group compared to the control group in the ESS
score (
−
2.3
±
2.3 vs. 0.6
±
3.3, p=0.003) (Table 4). There was no significant reduction in mixed
apnea in the CPAP treatment and control groups (
−
0.5
±
7.1 and
−
0.8
±
11.3, respectively; p=0.715).
Additionally, to confirm the correlation between improvement of the AHI by CPAP treatment and
cognitive improvement, the change of the K-MMSE score according to the improvement of AHI was
evaluated. In the regression analysis,
∆
K-MMSE (ß=0.071, 95% confidence interval [CI], 0.068–0.176,
p=0.033
) and
∆
ESS (ß=0.109, 95% CI, 0.096–0.257, p=0.002) were significantly correlated with
∆
AHI
(Table 5).
Brain Sci. 2019, 9, x FOR PEER REVIEW 7 of 12
ΔRecall (3) 0.3 ± 1.1 0.4 ± 0.6 0.558
ΔLanguage (8) 0.5 ± 0.9 0.8 ± 1.1 0.501
ΔDrawing (1) 0.1 ± 0.4 0.1 ± 0.6 0.710
ΔTotal (30) 4.0 ± 3.4 2.2 ± 1.9 0.045 *
Δ, difference in score between pre-intervention–post-intervention. CPAP, continuous positive airway
pressure. * p-value < 0.05.
3.2. Secondary Outcome Analysis (Sleep Examination Data)
CPAP treatment was performed for 3 weeks and follow-up evaluation was performed at 3 time
points after treatment (Figure 2). All patients in the CPAP treatment group received CPAP treatment
during the nighttime after the CPAP adaptation period, and they were highly compliant (>4 h/day,
≥5 days a week). However, in this study, compliance with CPAP treatment was not accurately
measured. During the hospital stay, the nurse in the ward checked the patients’ application of the
CPAP machine and educated the caregiver on how to measure the wearing time. As a result of the
sleep examination, the CPAP treatment group showed better improvement in the ESS score, central
apnea, obstructive apnea, AHI, snore flag index, and ODI than the control group. Especially, the
CPAP treatment group (n = 20) showed a significant decrease in the AHI (17.9 ± 12.8 vs. −3.0 ± 9.7, p
= 0.001) and obstructive apnea (−13.0 ± 14.1 vs. 1.6 ± 10.6, p = 0.001) compared with the control group.
In addition, significant improvement was observed in the CPAP treatment group compared to the
control group in the ESS score (−2.3 ± 2.3 vs. 0.6 ± 3.3, p = 0.003) (Table 4). There was no significant
reduction in mixed apnea in the CPAP treatment and control groups (−0.5 ± 7.1 and −0.8 ± 11.3,
respectively; p = 0.715). Additionally, to confirm the correlation between improvement of the AHI by
CPAP treatment and cognitive improvement, the change of the K-MMSE score according to the
improvement of AHI was evaluated. In the regression analysis, ΔK-MMSE (ß = 0.071, 95% confidence
interval [CI], 0.068–0.176, p = 0.033) and ΔESS (ß = 0.109, 95% CI, 0.096–0.257, p = 0.002) were
significantly correlated with ΔAHI (Table 5).
Figure 2. Study design. PSG, Polysomnography.
Table 4. Comparison of daytime sleepiness index and polysomnographic data between CPAP and
control group.
CPAP (n = 20) Control (n = 20) p-Value
ΔESS −2.3 ± 2.3 0.6 ± 3.3 0.003 *
ΔCentral apnea −2.7 ± 10.2 −0.2 ± 2.9 0.449
ΔObstructive apnea −13.0 ± 14.1 1.6 ± 10.6 0.001 *
ΔMixed apnea −0.5 ± 7.1 −0.8 ± 11.3 0.715
ΔHypopnea −1.8 ± 8.1 −3.7 ± 5.0 0.378
Figure 2. Study design. PSG, Polysomnography.

Brain Sci. 2019,9, 252 8 of 13
Table 4.
Comparison of daytime sleepiness index and polysomnographic data between CPAP and
control group.
CPAP (n=20) Control (n=20) p-Value
∆ESS −2.3 ±2.3 0.6 ±3.3 0.003 *
∆Central apnea −2.7 ±10.2 −0.2 ±2.9 0.449
∆Obstructive apnea −13.0 ±14.1 1.6 ±10.6 0.001 *
∆Mixed apnea −0.5 ±7.1 −0.8 ±11.3 0.715
∆Hypopnea −1.8 ±8.1 −3.7 ±5.0 0.378
∆AHI −17.9 ±12.8 −3.0 ±9.7 0.001 *
∆Snore flag index −23.5 ±54.8 0.7 ±70.3 0.441
∆Desaturation index −16.2 ±14.9 −7.7 ±19.6 0.133
∆
, difference in score between pre-intervention and post-intervention. CPAP, continuous positive airway pressure;
ESS, Epworth Sleepiness Scale; AHI, apnea–hypopnea index. * p-value <0.05.
Table 5. Regression analysis concerning CPAP treatment effectiveness.
βAdjusted R2p-Value
∆AHI
∆MMSE 0.071 0.114 0.033 *
∆ESS 0.109 0.220 0.002 *
∆
, difference score between pre-intervention and post-intervention. AHI, apnea–hypopnea index; MMSE, Korean
version of the Mini-Mental State Examination; ESS, Epworth Sleepiness Scale. * p-value <0.05.
4. Discussion
To the best of our knowledge, this is the first RCT to evaluate sleep quality and cognitive and
functional statuses in Korean patients with subacute stroke and OSA after CPAP treatment more than
3 weeks. We found that CPAP therapy can help improve cognitive function such as sleep quality
and sleepiness, as well as attention and calculation. Some of the main outcomes of the CPAP group,
such as cognitive outcome, severity of sleep apnea, and quality of sleep, improved, but improvement
in most assessments was not statistically significant compared to the control group. In contrast to
a previous study [
29
], we did not find significant improvements in the CPAP treatment group in
functional outcomes, including neurological status and ADL. Because the CPAP treatment group and
control group showed similar improvements in functional areas compared to before the intervention,
the role of rehabilitation therapy in the functional area may be judged to be more important than sleep
apnea treatment. However, since CPAP therapy was only performed during a short time, there may
be a limit to assessing the effectiveness of CPAP therapy in relation to patients’ functional outcome.
In addition, as the CPAP and rehabilitation group and CPAP-only group were not compared directly,
the superiority of each treatment could not be determined.
Previous studies have shown an improvement in cognitive function after OSA and stroke with
CPAP treatment, which is consistent with the results seen in patients of the CPAP treatment group
of the present study. We used the K-MMSE to evaluate cognitive function improvement and found
significant improvement in the attention and calculation domain [
49
,
50
]. Other studies have shown
that stroke patients with OSA have greater impairment in cognitive function, including attention and
executive function, than stroke patients without OSA [
14
]. We also compared daytime sleepiness
between the CPAP treatment and control groups, and found a better level of improvement in the CPAP
treatment group than in the control group. These results may have a positive impact on patients’
cognitive and functional improvement by inducing greater participation in the rehabilitation treatment
program. In this study, only 3 of the 23 patients in the CPAP group with OSA refused treatment.
The remaining patients were treated with CPAP for more than 4 hours a day for >3 weeks because all
the patients were hospitalized, and various medical professionals, such as doctors and nurses, who
were trained in CPAP treatment checked the patient’s condition at night and encouraged the use of

Brain Sci. 2019,9, 252 9 of 13
CPAP. Additionally, because SDB was diagnosed early, CPAP treatment could be applied early, which
could have resulted in the higher compliance with CPAP treatment.
A recent meta-analysis of CPAP treatment for sleep apnea in patients with stroke noted that sleep
apnea after stroke may affect perfusion and oxygenation of the penumbra, which may adversely affect
neural damage and stroke outcome [
39
,
51
]. The early application of CPAP may prolong survival of the
penumbra, resulting in clinical and imaging improvement in patients after stroke. Furthermore, the
application of ongoing CPAP therapy can independently contribute to improving cognitive impairment,
drowsiness, and depression, leading to better participation of the patient in the rehabilitation program,
which may have a more positive impact on recovery after stroke. Evidence for the beneficial effects
associated with neurological, cognitive, or long-term survival of CPAP after stroke have not yet been
clarified, but further RCTs and the present study may support a positive effect of CPAP therapy, as it
may be an additional treatment option for cognition and function improvement in patients with stroke.
This study has several limitations that remain to be addressed. First, the sample size of the
study was small. Of the 98 patients who underwent sleep examination, 43 were diagnosed with OSA
and only 40, except 3 patients who were withdrawn from the study because of medical condition
deterioration or refusal to CPAP treatment, participated in this RCT. The prevalence of sleep apnea in
this study was lower than that in previous studies (71%) [
52
] because we used strict diagnostic criteria
for OSA. Additionally, the use of portable polysomnography also tends to underestimate AHI. Portable
devices without electroencephalography recording capability cannot distinguish between awake and
sleep states. Therefore, it is possible that the number of patients who could participate in this study
was limited by this factor. Second, because of the limited hospitalization period, CPAP treatment
was performed during a short intervention period. To identify the effectiveness of CPAP treatment,
a 4-week or longer treatment period may be needed. Further, after the intervention period, the control
group was unable to perform CPAP treatment and did not perform long-term follow-up after discharge
to further evaluate the effect of CPAP treatment on OSA. Therefore, when interpreting the results of
this study, the characteristics of the hospital’s patients and the health policy situation in Korea should
be considered. Third, CPAP compliance may have increased because of treatment encouragement by
doctors and nurses rather than by family and caregivers. Since the CPAP machine itself is unable
to accurately monitor patients’ compliance, the accuracy of CPAP compliance cannot be confirmed.
Although continuing CPAP therapy may be beneficial to patients after discharge, there may be a limit to
the maintenance of CPAP treatment if the family or caregivers do not receive awareness or training for
CPAP treatment. Maintaining high CPAP compliance over a prolonged period may be more beneficial
for the patient. Fourth, patients did not undergo a sleep examination before the diagnosis of stroke.
Therefore, it was not possible to determine whether they already had sleep apnea. Previous studies
have suggested that sleep apnea is more likely to precede the onset of stroke and that sleep apnea
improves in most patients after the acute phase of stroke [
18
,
52
]. Fifth, patients with severe neurological
deficits showed more severe sleep apnea but no significant functional improvement in CPAP treatment.
This study compared the mean values of patients with various severities of stroke, and consequently,
the severity of stroke may directly affect the efficacy of CPAP treatment. Lastly, neurostimulants such
as methylphenidate have not been used, but we did not evaluate sleep-related medications (sedatives)
in subacute stroke patients with OSA. Therefore, aside from using CPAP, we could not confirm the
change of sleep quality or weekly daytime sleepiness caused by sleep-related medication.
5. Conclusions
Sleep apnea is a common disease in patients with subacute stroke, and it can aggravate neurological
and functional statuses. Clinicians should assess patients’ sleep status and adequately treat sleep
disturbances during the rehabilitation of subacute stroke. The beneficial effects of CPAP treatment
found in this study suggest that this treatment should be considered as part of the rehabilitation program
for patients with stroke. The treatment of choice for OSA is CPAP treatment. When applied to subacute
stroke patients with OSA for a short period, there was improvement in sleep quality, daytime sleepiness,

Brain Sci. 2019,9, 252 10 of 13
and cognitive function. Patients with high compliance and long-term CPAP treatment may have
a greater benefit. Appropriate CPAP treatment can improve patients’ overall function by improving
their cognitive function and daytime sleepiness, and consequently, inducing their participation in
a rehabilitation program. Further research is needed on the improvements in neurological and
functional statuses among stroke patients who have received long-term CPAP treatment.
Author Contributions:
The following authors devised of and designed the study: H.K., Y.K. and S.J.; data
collection and analysis: H.K., S.I. and J.i.P., Y.K. and M.K.S.; contributed to writing the manuscript: H.K., M.K.S.
and S.J.
Funding:
This study was supported by grants (HI10C2020) from the Korean Health Technology R&D Project,
Ministry of Health & Welfare, from NRF- 2015R1C1A1A01055923, NRF-2017R1A2B4006500 and VitalAire Korea Inc.
Conflicts of Interest: No potential conflict of interest relevant to this article was reported.
References
1.
Benjamin, E.J.; Virani, S.S.; Callaway, C.W.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Chiuve, S.E.;
Cushman, M.; Delling, F.N.; Deo, R.; et al. Heart Disease and Stroke Statistics—2018 Update: A Report from
the American Heart Association. Circulation 2018,137, e67–e492. [CrossRef] [PubMed]
2.
Miniño, A.M.; Xu, J.; Kochanek, K. Deaths: Preliminary data for 2008. Natl. Vital Stat. Rep.
2010
,59, 1–52.
[PubMed]
3.
Gordon, N.F.; Gulanick, M.; Costa, F.; Fletcher, G.; Franklin, B.A.; Roth, E.J.; Shephard, T. Physical activity
and exercise recommendations for stroke survivors: An American Heart Association scientific statement
from the Council on Clinical Cardiology, Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention;
the Council on Cardiovascular Nursing; the Council on Nutrition, Physical Activity, and Metabolism; and
the Stroke Council. Stroke 2004,35, 1230–1240. [PubMed]
4.
De Oliveira, C.B.; De Medeiros, I.R.T.; Frota, N.A.F.; Greters, M.E.; Conforto, A.B. Balance control in
hemiparetic stroke patients: Main tools for evaluation. J. Rehabil. Res. Dev.
2008
,45, 1215–1226. [CrossRef]
[PubMed]
5.
Kernan, W.N.; Ovbiagele, B.; Black, H.R.; Bravata, D.M.; Chimowitz, M.I.; Ezekowitz, M.D.; Fang, M.C.;
Fisher, M.; Furie, K.L.; Heck, D.V.; et al. Guidelines for the Prevention of Stroke in Patients with
Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals from the American
Heart Association/American Stroke Association. Stroke 2014,45, 2160–2236. [CrossRef]
6.
Sethi, N.K.; Sacchetti, M.L.; Davis, A.P.; Billings, M.E.; Longstreth, W.T.; Khot, S.P. Early diagnosis and
treatment of obstructive sleep apnea after stroke: Are we neglecting a modifiable stroke risk factor? Neurol.
Clin. Pract. 2013,3, 192–201. [CrossRef]
7.
Shahar, E.; Whitney, C.W.; Redline, S.; Lee, E.T.; Newman, A.B.; Javier Nieto, F.; O’Connor, G.T.; Boland, L.L.;
Schwartz, J.E.; Samet, J.M. Sleep-disordered breathing and cardiovascular disease: Cross-sectional results of
the Sleep Heart Health Study. Am. J. Respir. Crit. Care Med. 2001,163, 19–25. [CrossRef]
8.
Yaggi, H.K.; Concato, J.; Kernan, W.N.; Lichtman, J.H.; Brass, L.M.; Mohsenin, V. Obstructive Sleep Apnea as
a Risk Factor for Stroke and Death. N. Engl. J. Med. 2005,353, 2034–2041. [CrossRef]
9.
Lattimore, J.L.; Wilcox, I.; Skilton, M.; Langenfeld, M.; Celermajer, D.S. Treatment of obstructive sleep apnoea
leads to improved microvascular endothelial function in the systemic circulation. Thorax
2006
,61, 491–495.
[CrossRef]
10.
Drager, L.F.; Bortolotto, L.A.; Figueiredo, A.C.; Krieger, E.M.; Lorenzi-Filho, G. Effects of Continuous Positive
Airway Pressure on Early Signs of Atherosclerosis in Obstructive Sleep Apnea. Am. J. Respir. Crit. Care Med.
2007,176, 706–712. [CrossRef]
11.
Minoguchi, K.; Yokoe, T.; Tazaki, T.; Minoguchi, H.; Oda, N.; Tanaka, A.; Yamamoto, M.; Ohta, S.;
O’Donnell, C.P.; Adachi, M. Silent brain infarction and platelet activation in obstructive sleep apnea. Am. J.
Respir. Crit. Care Med. 2007,175, 612–617. [CrossRef] [PubMed]
12.
Arzt, M.; Young, T.; Finn, L.; Skatrud, J.B.; Bradley, T.D. Association of sleep-disordered breathing and the
occurrence of stroke. Am. J. Respir. Crit. Care Med. 2005,172, 1447–1451. [CrossRef] [PubMed]

Brain Sci. 2019,9, 252 11 of 13
13.
Klobuˇcn
í
kov
á
, K.; Šiarnik, P.; ˇ
Carnick
á
, Z.; Koll
á
r, B.; Turˇc
á
ni, P. Causes of Excessive Daytime Sleepiness
in Patients with Acute Stroke—A Polysomnographic Study. J. Stroke Cerebrovasc. Dis.
2016
,25, 83–86.
[CrossRef] [PubMed]
14.
Aaronson, J.A.; Van Bennekom, C.A.; Hofman, W.F.; Van Bezeij, T.; Aardweg, J.G.V.D.; Groet, E.; Kylstra, W.A.;
Schmand, B. Obstructive Sleep Apnea is Related to Impaired Cognitive and Functional Status after Stroke.
Sleep 2015,38, 1431–1437. [CrossRef] [PubMed]
15.
Mohsenin, V.; Valor, R. Sleep apnea in patients with hemispheric stroke. Arch. Phys. Med. Rehabil.
1995
,76,
71–76. [CrossRef]
16.
Martinez-Garcia, M.A.; Galiano-Blancart, R.; Soler-Cataluna, J.J.; Cabero-Salt, L.; Roman-Sanchez, P.
Improvement in nocturnal disordered breathing after first-ever ischemic stroke: Role of dysphagia. Chest
2006,129, 238–245. [CrossRef] [PubMed]
17.
Yan-fang, S.; Yu-ping, W. Sleep-disordered breathing: Impact on functional outcome of ischemic stroke
patients. Sleep Med. 2009,10, 717–719. [CrossRef] [PubMed]
18.
Bassetti, C.L.; Milanova, M.; Gugger, M. Sleep-disordered breathing and acute ischemic stroke: Diagnosis,
risk factors, treatment, evolution, and long-term clinical outcome. Stroke
2006
,37, 967–972. [CrossRef]
[PubMed]
19.
Camilo, M.R.; Schnitman, S.V.; Sander, H.H.; Eckeli, A.L.; Fernandes, R.M.; Leite, J.P.; Bassetti, C.L.;
Pontes-Neto, O.M. Sleep-disordered breathing among acute ischemic stroke patients in Brazil. Sleep Med.
2016,19, 8–12. [CrossRef] [PubMed]
20.
Hermann, D.M.; Bassetti, C.L. Sleep-related breathing and sleep-wake disturbances in ischemic stroke.
Neurology 2009,73, 1313–1322. [CrossRef] [PubMed]
21.
Dyken, M.E.; Somers, V.K.; Yamada, T.; Ren, Z.Y.; Zimmerman, M.B. Investigating the relationship between
stroke and obstructive sleep apnea. Stroke 1996,27, 401–407. [CrossRef] [PubMed]
22.
Joo, B.E.; Seok, H.Y.; Yu, S.W.; Kim, B.J.; Park, K.W.; Lee, D.H.; Jung, K.Y. Prevalence of sleep-disordered
breathing in acute ischemic stroke as determined using a portable sleep apnea monitoring device in Korean
subjects. Sleep Breath. 2011,15, 77–82. [CrossRef]
23.
Jeon, H.; Sohn, M.K.; Jeon, M.; Jee, S. Clinical Characteristics of Sleep-Disordered Breathing in Subacute
Phase of Stroke. Ann. Rehabil. Med. 2017,41, 556–563. [CrossRef] [PubMed]
24.
Iranzo, A.; Santamaria, J.; Berenguer, J.; S
á
nchez, M.; Chamorro, A. Prevalence and clinical importance of
sleep apnea in the first night after cerebral infarction. Neurology 2002,58, 911–916. [CrossRef] [PubMed]
25.
Nopmaneejumruslers, C.; Kaneko, Y.; Hajek, V.; Zivanovic, V.; Bradley, T.D. Cheyne-Stokes respiration in
stroke: Relationship to hypocapnianand occult cardiac dysfunction. Am. J. Respir. Crit. Care Med.
2005
,171,
1048–1052. [CrossRef] [PubMed]
26.
Mart
í
nez-Garc
í
a, M.A.; Soler-Cataluña, J.J.; Ejarque-Mart
í
nez, L.; Soriano, Y.; Rom
á
n-S
á
nchez, P.; Illa, F.B.;
Canal, J.M.; Dur
á
n-Cantolla, J. Continuous positive airway pressure treatment reduces mortality in patients
with ischemic stroke and obstructive sleep apnea: A 5-year follow-up study. Am. J. Respir. Crit. Care Med.
2009,180, 36–41. [CrossRef] [PubMed]
27.
Parra, O.; Arboix, A.; Montserrat, J.; Quint
ó
, L.; Bechich, S.; Garc
í
a-Eroles, L. Sleep-related breathing disorders:
Impact on mortality of cerebrovascular disease. Eur. Respir. J. 2004,24, 267–272. [CrossRef]
28.
Sahlin, C.; Sandberg, O.; Gustafson, Y.; Bucht, G.; Carlberg, B.; Stenlund, H.; Franklin, K.A. Obstructive sleep
apnea is a risk factor for death in patients with stroke: A 10-year follow-up. Arch. Intern. Med.
2008
,168,
297–301. [CrossRef] [PubMed]
29.
Ryan, C.M.; Bayley, M.; Green, R.; Murray, B.J.; Bradley, T.D. Influence of continuous positive airway pressure
on outcomes of rehabilitation in stroke patients with obstructive sleep apnea. Stroke
2011
,42, 1062–1067.
[CrossRef]
30.
Turkington, P.; Bamford, J.; Wanklyn, P.; Elliott, M. Prevalence and predictors of upper airway obstruction in
the first 24 hours after acute stroke. Stroke 2002,33, 2037–2042. [CrossRef]
31.
Broadley, S.A.; Jørgensen, L.; Cheek, A.; Salonikis, S.; Taylor, J.; Thompson, P.D.; Antic, R. Early investigation
and treatment of obstructive sleep apnoea after acute stroke. J. Clin. Neurosci.
2007
,14, 328–333. [CrossRef]
[PubMed]
32.
Johnson, K.G.; Johnson, D.C. Frequency of Sleep Apnea in Stroke and TIA Patients: A Meta-analysis. J. Clin.
Sleep Med. 2010,6, 131–137. [PubMed]

Brain Sci. 2019,9, 252 12 of 13
33.
Lisabeth, L.D.; S
á
nchez, B.N.; Chervin, R.D.; Morgenstern, L.B.; Zahuranec, D.B.; Tower, S.D.; Brown, D.L.
High prevalence of poststroke sleep-disordered breathing in Mexican Americans. Sleep Med.
2017
,33, 97–102.
[CrossRef] [PubMed]
34.
Rola, R.; Wierzbicka, A.; Wichniak, A.; Jernajczyk, W.; Richter, P.; Ryglewicz, D. Sleep related breathing
disorders in patients with ischemic stroke and transient ischemic attacks: Respiratory and clinical correlations.
J. Physiol. Pharmacol. 2007,58 (Suppl. S5), 575–582. [PubMed]
35.
Sullivan, C.; Berthon-Jones, M.; Issa, F.; Eves, L. Reversal of obstructive sleep apnoea by continuous positive
airway pressure applied through the nares. Lancet 1981,1, 862–865. [CrossRef]
36.
Montserrat, J.M.; Ferrer, M.; Hernandez, L.; Farr
é
, R.; Vilagut, G.; Navajas, D.; Badia, J.R.; Carrasco, E.V.A.; De
Pablo, J.U.; Ballester, E.; et al. Effectiveness of CPAP treatment in daytime function in sleep apnea syndrome:
A randomized controlled study with an optimized placebo. Am. J. Respir. Crit. Care Med.
2001
,164, 608–613.
[CrossRef]
37.
Sutherland, B.A.; Minnerup, J.; Balami, J.S.; Arba, F.; Buchan, A.M.; Kleinschnitz, C. Neuroprotection for
Ischaemic Stroke: Translation from the Bench to the Bedside. Int. J. Stroke
2012
,7, 407–418. [CrossRef]
[PubMed]
38.
Parra, O.; S
á
nchez-Armengol, A.; Bonnin, M.; Arboix, A.; Campos-Rodr
í
guez, F.; P
é
rez-Ronchel, J.;
Dur
á
n-Cantolla, J.; de la Torre, G.; Marcos, J.G.; de la Peña, M.; et al. Early treatment of obstructive
apnoea and stroke outcome: A randomised controlled trial. Eur. Respir. J. 2011,37, 1128–1136. [CrossRef]
39.
Brill, A.K.; Horvath, T.; Seiler, A.; Camilo, M.; Haynes, A.G.; Ott, S.R.; Egger, M.; Bassetti, C.L. CPAP as
treatment of sleep apnea after stroke: A meta-analysis of randomized trials. Neurology
2018
,90, e1222–e1230.
[CrossRef]
40.
Parra, O.; S
á
nchez-Armengol,
Á
.; Capote, F.; Bonnin, M.; Arboix, A.; Campos-Rodr
í
guez, F.; P
é
rez-Ronchel, J.;
Durán-Cantolla, J.; Martínez-Null, C.; de la Peña, M.; et al. Efficacy of continuous positive airway pressure
treatment on 5-year survival in patients with ischaemic stroke and obstructive sleep apnea: A randomized
controlled trial. J. Sleep Res. 2015,24, 47–53. [CrossRef]
41.
Sandberg, O.; Franklin, K.; Bucht, G.; Eriksson, S.; Gustafson, Y. Nasal continuous positive airway pressure
in stroke patients with sleep apnoea: A randomized treatment study. Eur. Respir. J.
2001
,18, 630–634.
[CrossRef] [PubMed]
42.
Epstein, L.J.; Kristo, D.; Strollo, P.J.; Friedman, N.; Malhotra, A.; Patil, S.P.; Ramar, K.; Rogers, R.; Schwab, R.J.;
Weaver, E.M.; et al. Clinical Guideline for the Evaluation, Management and Long-term Care of Obstructive
Sleep Apnea in Adults. J. Clin. Sleep Med. 2009,5, 263–276. [PubMed]
43.
Collop, N.A.; Anderson, W.M.; Boehlecke, B.; Claman, D.; Goldberg, R.; Gottlieb, D.J.; Hudgel, D.; Sateia, M.;
Schwab, R. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive
sleep apnea in adult patients: Portable Monitoring Task Force of the American Academy of Sleep Medicine.
J. Clin. Sleep Med. 2007,3, 737–747. [PubMed]
44.
Berry, R.B.; Budhiraja, R.; Gottlieb, D.J.; Gozal, D.; Iber, C.; Kapur, V.K.; Marcus, C.L.; Mehra, R.;
Parthasarathy, S.; Quan, S.F.; et al. Rules for Scoring Respiratory Events in Sleep: Update of the 2007 AASM
Manual for the Scoring of Sleep and Associated Events. J. Clin. Sleep Med.
2012
,8, 597–619. [CrossRef]
[PubMed]
45.
Johns, M.W. Sleepiness in different situations measured by the Epworth Sleepiness Scale. Sleep
1994
,17,
703–710. [CrossRef] [PubMed]
46.
Cho, Y.W.; Lee, J.H.; Son, H.K.; Lee, S.H.; Shin, C.; Johns, M.W. The reliability and validity of the Korean
version of the Epworth sleepiness scale. Sleep Breath. 2011,15, 377–384. [CrossRef] [PubMed]
47.
Han, N.E.; Kim, D.Y.; Lee, S.-A. Validity of Korean Version of Functional Outcomes of Sleep Questionnaire in
Patients with Simple Snoring and Obstructive Sleep Apnea. Sleep Med. Res. 2014,5, 5–14. [CrossRef]
48.
Tombaugh, T.N.; McIntyre, N.J. The Mini-Mental State Examination: A Comprehensive Review. J. Am.
Geriatr. Soc. 1992,40, 922–935. [CrossRef]
49.
Kylstra, W.A.; Aaronson, J.A.; Hofman, W.F.; Schmand, B.A. Neuropsychological functioning after CPAP
treatment in obstructive sleep apnea: A meta-analysis. Sleep Med. Rev. 2013,17, 341–347. [CrossRef]
50.
Olaithe, M.; Bucks, R.S. Executive dysfunction in OSA before and after treatment: A meta-analysis. Sleep
2013,36, 1297–1305. [CrossRef]

Brain Sci. 2019,9, 252 13 of 13
51.
Duss, S.B.; Seiler, A.; Schmidt, M.H.; Pace, M.; Adamantidis, A.; Müri, R.M.; Bassetti, C.L. The role of sleep in
recovery following ischemic stroke: A review of human and animal data. Neurobiol. Sleep Circadian Rhythms
2017,2, 94–105. [CrossRef] [PubMed]
52.
Parra, O.; Arboix, A.; Bechich, S.; Garc
í
a-Eroles, L.; Montserrat, J.M.; L
ó
pez, J.A.; Ballester, E.; Guerra, J.M.;
Sopeña, J.J. Time Course of Sleep-related Breathing Disorders in First-Ever Stroke or Transient Ischemic
Attack. Am. J. Respir. Crit. Care Med. 2000,161, 375–380. [CrossRef] [PubMed]
©
2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).